Noul, Biomedica sign exclusive European deal for AI cervical cancer diagnostic solution
November 10, 2025 — Noul, Korea’s AI-based blood and cancer diagnostics company, said Monday it has signed an exclusive distribution agreement with Biomedica, a leading European medical device distributor, for its cervical cancer diagnostic solution miLab CER.
The deal marks Noul’s first distribution contract for a cervical cancer diagnostic solution in Europe and allows entry into the region through the verified network of “the world’s No. 1” cervical cancer diagnostics company, Noul said.
Biomedica, a major player in Europe’s diagnostics and medical device distribution market for over 40 years, operates under one of the continent’s top healthcare groups with annual sales of about 1.6 trillion won. It serves as the exclusive distributor for the world’s top cervical cancer diagnostics firm in Eastern Europe, maintaining a wide sales network across 16 European countries, including Austria, Switzerland, Hungary, Romania, and Poland.
Noul’s cervical cancer diagnostic solution miLab CER (Courtesy of Noul)
Through this partnership, Noul will distribute miLab CER alongside the world’s leading liquid-based cytology (LBC) equipment via Biomedica’s network. The AI-powered platform automates staining, image capture, and AI analysis using LBC slides. Sales will begin in six Eastern European countries, including the Czech Republic, Hungary, and Poland, before expanding across Europe.
“This partnership is a strategic move that will significantly accelerate Noul’s market entry in Europe through the proven sales network of the world’s top cervical cancer diagnostics company,” said David Lim, CEO of Noul. “We plan to successfully install miLab CER in Eastern European hospitals this year and expand sales across Europe next year, boosting revenue, improving profitability, and securing global growth momentum.”
Across Europe, more than 60,000 women are diagnosed with cervical cancer each year and over 30,000 die from the disease. Mortality rates in Eastern Europe are up to three times higher than in Western Europe, while screening participation varies from 22 percent to 80 percent by country. The World Health Organization (WHO) aims to raise global cervical cancer screening rates from 30 percent to 70 percent by 2030.
Noul’s miLab CER streamlines cytopathology from 25 steps to just five, improving diagnostic efficiency, speed, and accuracy. The 2024 WHO–UNITAID report recognized miLab CER — alongside Roche and Hologic — as one of the world’s top three cervical cancer diagnostic solutions.
Meanwhile, Noul has begun shipments to Qatar and Panama, signed an MOU with Seegene Brazil for local supply, and secured regulatory approvals in the U.K., Switzerland, Vietnam, and the Philippines, accelerating its global expansion.
SOURCE: Korea Biomedical Review
